Please see the full Prescribing Information for STELARA® for adequate directions for use for the approved indications.
STELARA® (ustekinumab) is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis:
Induction dose: A single intravenous infusion using weight-based dosage regimen: 260 mg (weight ≤55 kg), 390 mg (weight >55 kg to 85 kg), or 520 mg (weight >85 kg).
Maintenance dose: A subcutaneous 90-mg dose administered every 8 weeks after the induction dose. STELARA® can be administered by a healthcare provider or by the patient after physician approval and proper training.1
Do you want to leave STELARAhcp.com to access this clinical reprint?